| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Chlordiazepoxide | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | | Chlordiazepoxide | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | | Chlordiazepoxide | hsa00380 | Tryptophan metabolism | 4.14E-02 | 1 | Q16613 | AANAT | More | | | Chlordiazepoxide | hsa00500 | Starch and sucrose metabolism | 1.47E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Chlordiazepoxide | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | | Chlordiazepoxide | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | | | Chlordiazepoxide | hsa00730 | Thiamine metabolism | 4.07E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Chlordiazepoxide | hsa00830 | Retinol metabolism | 4.25E-02 | 1 | P00325 | ADH1B | More | | | Chlordiazepoxide | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | | Chlordiazepoxide | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | | Chlordiazepoxide | hsa01523 | Antifolate resistance | 1.01E-04 | 5 | P41439, P41440, Q92820, P04818, P01375 | FOLR3, SLC19A1, GGH, TYMS, TNF | More | | | Chlordiazepoxide | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | | Chlordiazepoxide | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | | Chlordiazepoxide | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | | | Chlordiazepoxide | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | | Chlordiazepoxide | hsa03015 | mRNA surveillance pathway | 1.83E-02 | 3 | Q13362, Q14738, Q9UBU9 | PPP2R5C, PPP2R5D, NXF1 | More | | | Chlordiazepoxide | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | | | Chlordiazepoxide | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Chlordiazepoxide | hsa03040 | Spliceosome | 1.46E-02 | 4 | P17844, P51991, P61978, P11142 | DDX5, HNRPA3, HNRPK, HSPA8 | More | | | Chlordiazepoxide | hsa03050 | Proteasome | 1.40E-02 | 1 | P55036 | PSMD4 | More | | | Chlordiazepoxide | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | | Chlordiazepoxide | hsa04024 | cAMP signaling pathway | 3.37E-02 | 3 | P63092, P26678, P61586 | GNAS, PLN, RHOA | More | | | Chlordiazepoxide | hsa04064 | NF-kappa B signaling pathway | 4.36E-04 | 11 | P10415, O00463, P14778, Q04759, Q9UDY8, Q13077, Q16548, Q8WV28, Q13315, P24522, P09341 | BCL2, TRAF5, IL1R1, PRKCQ, MALT1, TRAF1, BCL2A1, BLNK, ATM, GADD45A, CXCL1 | More | | | Chlordiazepoxide | hsa04071 | Sphingolipid signaling pathway | 6.65E-04 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | | Chlordiazepoxide | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | | | Chlordiazepoxide | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | | | Chlordiazepoxide | hsa04110 | Cell cycle | 1.97E-05 | 7 | P06493, O60566, O75293, P30304, P33981, P42773, P01106 | CDK1, BUB1B, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | | Chlordiazepoxide | hsa04114 | Oocyte meiosis | 3.65E-02 | 3 | P0DP23, Q13362, Q14738 | CALM1, PPP2R5C, PPP2R5D | More | | | Chlordiazepoxide | hsa04120 | Ubiquitin mediated proteolysis | 1.44E-04 | 7 | Q9UBT2, Q14145, Q13042, Q13191, Q15751, Q14669, Q7Z6Z7 | SAE2, KEAP1, CDC16, CBLB, HERC1, TRIP12, HUWE1 | More | | | Chlordiazepoxide | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | | | Chlordiazepoxide | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | | Chlordiazepoxide | hsa04141 | Protein processing in endoplasmic reticulum | 3.42E-04 | 7 | P18848, Q15437, O60337, Q99941, P11142, P07900, Q9NR31 | ATF4, SEC23B, MARH6, CREBL1, HSPA8, HSP90AA1, SAR1A | More | | | Chlordiazepoxide | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | | | Chlordiazepoxide | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | | | Chlordiazepoxide | hsa04151 | PI3K-Akt signaling pathway | 3.91E-03 | 7 | P62753, P27348, P07900, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, TNXB, CREBL1, ATF4, SGK | More | | | Chlordiazepoxide | hsa04152 | AMPK signaling pathway | 1.83E-02 | 3 | Q96RR4, Q13362, Q14738 | CAMKK2, PPP2R5C, PPP2R5D | More | | | Chlordiazepoxide | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | | Chlordiazepoxide | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | | Chlordiazepoxide | hsa04217 | Necroptosis | 4.42E-04 | 6 | P07900, P15104, P05141, P01584, P0C0S5, Q13557 | HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D | More | | | Chlordiazepoxide | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | | Chlordiazepoxide | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.59E-03 | 7 | P51828, Q99941, P18848, Q13362, Q14738, P0DP23, Q13557 | ADCY7, CREBL1, ATF4, PPP2R5C, PPP2R5D, CALM1, CAMK2D | More | | | Chlordiazepoxide | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | | | Chlordiazepoxide | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | | Chlordiazepoxide | hsa04510 | Focal adhesion | 4.07E-02 | 3 | O14986, P61586, Q16363 | PIP5K1B, RHOA, LAMA4 | More | | | Chlordiazepoxide | hsa04520 | Adherens junction | 1.38E-04 | 3 | P19784, P67870, P61586 | CSNK2A2, CSNK2B, RHOA | More | | | Chlordiazepoxide | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | | Chlordiazepoxide | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | | | Chlordiazepoxide | hsa04613 | Neutrophil extracellular trap formation | 2.06E-04 | 16 | O60603, P05164, P08246, Q9UM07, P04908, Q6FI13, Q93077, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Chlordiazepoxide | hsa04621 | NOD-like receptor signaling pathway | 4.31E-02 | 4 | P01375, P59665, P59666, P12838 | TNF, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | | Chlordiazepoxide | hsa04640 | Hematopoietic cell lineage | 4.71E-03 | 5 | P21926, P07766, P01730, P06127, P09564 | CD9, CD3E, CD4, CD5, CD7 | More | | | Chlordiazepoxide | hsa04650 | Natural killer cell mediated cytotoxicity | 3.18E-03 | 8 | P01375, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | | Chlordiazepoxide | hsa04657 | IL-17 signaling pathway | 5.20E-04 | 10 | P07900, O00463, Q16539, P49841, P09341, P14780, Q9UJX4, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL1, MMP9, ANAPC5, LCN2, TNF, IL1B | More | | | Chlordiazepoxide | hsa04658 | Th1 and Th2 cell differentiation | 1.07E-03 | 7 | Q04759, P20963, P09693, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, STAT4, GATA3, TBX21, HLA-DOB | More | | | Chlordiazepoxide | hsa04659 | Th17 cell differentiation | 1.90E-02 | 6 | Q04759, P13765, Q9UL17, P23771, P09693, P20963 | PRKCQ, HLA-DOB, TBX21, GATA3, CD3G, CD247 | More | | | Chlordiazepoxide | hsa04660 | T cell receptor signaling pathway | 1.00E-02 | 7 | Q9UDY8, Q04759, P10747, Q08881, P20963, P09693, P01732 | MALT1, PRKCQ, CD28, ITK, CD247, CD3G, CD8A | More | | | Chlordiazepoxide | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | | | Chlordiazepoxide | hsa04714 | Thermogenesis | 6.01E-04 | 8 | Q16539, P51828, P62753, P33121, P12074, O15239, Q16718, O14521 | MAPK14, ADCY7, RPS6, ACSL1, COX6A1, NDUFA1, NDUFA5, SDHD | More | | | Chlordiazepoxide | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | | | Chlordiazepoxide | hsa04724 | Glutamatergic synapse | 3.65E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | | Chlordiazepoxide | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | | Chlordiazepoxide | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | | | Chlordiazepoxide | hsa04728 | Dopaminergic synapse | 3.20E-03 | 6 | Q99941, P18848, Q13557, Q13362, Q14738, P0DP23 | CREBL1, ATF4, CAMK2D, PPP2R5C, PPP2R5D, CALM1 | More | | | Chlordiazepoxide | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | | Chlordiazepoxide | hsa04912 | GnRH signaling pathway | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | | Chlordiazepoxide | hsa04915 | Estrogen signaling pathway | 2.75E-03 | 5 | Q99941, P18848, P51828, P07900, P11142 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | | | Chlordiazepoxide | hsa04918 | Thyroid hormone synthesis | 1.69E-03 | 4 | P51828, Q99941, P18848, P02768 | ADCY7, CREBL1, ATF4, ALB | More | | | Chlordiazepoxide | hsa04921 | Oxytocin signaling pathway | 3.13E-02 | 3 | P0DP23, Q96RR4, Q13469 | CALM1, CAMKK2, NFATC2 | More | | | Chlordiazepoxide | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | | Chlordiazepoxide | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | | Chlordiazepoxide | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | | Chlordiazepoxide | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | | Chlordiazepoxide | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | | Chlordiazepoxide | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.09E-03 | 7 | Q14643, P51828, P22694, P23771, Q99941, P18848, P10415 | ITPR1, ADCY7, PRKACB, GATA3, CREBL1, ATF4, BCL2 | More | | | Chlordiazepoxide | hsa04932 | Non-alcoholic fatty liver disease | 9.01E-04 | 7 | P49841, P18848, P01584, P13073, O15239, Q16718, O14521 | GSK3B, ATF4, IL1B, COX4I1, NDUFA1, NDUFA5, SDHD | More | | | Chlordiazepoxide | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | | Chlordiazepoxide | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | | Chlordiazepoxide | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Chlordiazepoxide | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | | Chlordiazepoxide | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | | Chlordiazepoxide | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | | | Chlordiazepoxide | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Chlordiazepoxide | hsa04979 | Cholesterol metabolism | 1.61E-02 | 2 | P38571, P61916 | LIPA, NPC2 | More | | | Chlordiazepoxide | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | | | Chlordiazepoxide | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | | | Chlordiazepoxide | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | | | Chlordiazepoxide | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.47E-03 | 12 | P49841, O15239, Q16718, O14521, P13073, P18848, Q13561, P05141, Q16539, P01584, Q08752, Q13557 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, DCTN2, SLC25A5, MAPK14, IL1B, PPID, CAMK2D | More | | | Chlordiazepoxide | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | | Chlordiazepoxide | hsa05031 | Amphetamine addiction | 6.41E-03 | 3 | Q13557, Q99941, P18848 | CAMK2D, CREBL1, ATF4 | More | | | Chlordiazepoxide | hsa05032 | Morphine addiction | 9.04E-05 | 5 | P62873, P48169, P78334, P63092, P32298 | GNB1, GABRA4, GABRE, GNAS, GRK4 | More | | | Chlordiazepoxide | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.45E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | | Chlordiazepoxide | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | | Chlordiazepoxide | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | | | Chlordiazepoxide | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | | | Chlordiazepoxide | hsa05142 | Chagas disease | 2.26E-02 | 3 | P01375, P30679, P48023 | TNF, GNA15, FASLG | More | | | Chlordiazepoxide | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | | Chlordiazepoxide | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | | Chlordiazepoxide | hsa05146 | Amoebiasis | 4.55E-02 | 5 | P09341, P14778, P27930, O60603, P05089 | CXCL1, IL1R1, IL1R2, TLR2, ARG1 | More | | | Chlordiazepoxide | hsa05150 | Staphylococcus aureus infection | 1.83E-02 | 3 | P59665, P59666, P12838 | DEFA1; DEFA1B, DEFA3, DEFA4 | More | | | Chlordiazepoxide | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | | Chlordiazepoxide | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | | | Chlordiazepoxide | hsa05163 | Human cytomegalovirus infection | 4.65E-03 | 11 | P62873, Q14643, P61586, P49841, P14778, P25025, Q16539, P63092, P04637, O00463, P61769 | GNB1, ITPR1, RHOA, GSK3B, IL1R1, CXCR2, MAPK14, GNAS, TP53, TRAF5, B2M | More | | | Chlordiazepoxide | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.82E-02 | 3 | P23458, Q13469, P0DP23 | JAK1, NFATC2, CALM1 | More | | | Chlordiazepoxide | hsa05171 | Coronavirus disease - COVID-19 | 3.15E-04 | 9 | P01584, P62753, P25398, Q9UHA3, P36578, P32969, P18077, P62829, O14786 | IL1B, RPS6, RPS12, RSL24D1, RPL4, RPL9, RPL35A, RPL23, NRP1 | More | | | Chlordiazepoxide | hsa05202 | Transcriptional misregulation in cancer | 1.40E-03 | 15 | Q12778, Q15532, Q13315, P41732, P14780, P27930, P14923, Q16548, Q13077, O15550, P35226, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, TRAF1, UTX, BMI1, MPO, ELA2, BCL11B, GADD45A | More | | | Chlordiazepoxide | hsa05203 | Viral carcinogenesis | 1.46E-02 | 4 | Q99941, P18848, P27348, P61978 | CREBL1, ATF4, YWHAQ, HNRPK | More | | | Chlordiazepoxide | hsa05212 | Pancreatic cancer | 4.16E-02 | 2 | Q15311, P23458 | RALBP1, JAK1 | More | | | Chlordiazepoxide | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | | Chlordiazepoxide | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | | Chlordiazepoxide | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | | Chlordiazepoxide | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | | Chlordiazepoxide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.69E-04 | 11 | O95267, P07766, P20963, P09693, P06239, O60603, P10747, Q04759, Q16539, Q9HC35, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ, MAPK14, EML4, CD4 | More | | | Chlordiazepoxide | hsa05321 | Inflammatory bowel disease | 1.17E-03 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | | | Chlordiazepoxide | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | | Chlordiazepoxide | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Chlordiazepoxide | hsa05332 | Graft-versus-host disease | 3.49E-05 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | | Chlordiazepoxide | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | | Chlordiazepoxide | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | | Chlordiazepoxide | hsa05415 | Diabetic cardiomyopathy | 1.02E-03 | 8 | P05141, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557 | SLC25A5, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D | More | | | Chlordiazepoxide | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | |
|
